Thermo Fisher Reports Strong Q1 Results Despite Stock Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy TMO?
Source: seekingalpha
Thermo Fisher Scientific's stock is down 8.17% in pre-market trading, hitting a 5-day low amid broader market weakness with the Nasdaq-100 and S&P 500 both down 0.22%.
Despite the stock decline, Thermo Fisher reported Q1 revenue of $11.01 billion, exceeding market expectations by $150 million and reflecting a 6% year-over-year growth, primarily driven by strong performance in the Life Sciences Solutions segment. However, the company's non-GAAP organic revenue growth was only 1%, missing the analyst estimate of 1.2%, which raises concerns about future growth potential and market confidence.
The mixed results indicate that while Thermo Fisher maintains strong revenue figures, the slower organic growth could lead to a reassessment of its investment value, especially as it ranks lower compared to peers like Mettler-Toledo, which received higher ratings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TMO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TMO
Wall Street analysts forecast TMO stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 466.700
Low
580.00
Averages
658.89
High
750.00
Current: 466.700
Low
580.00
Averages
658.89
High
750.00
About TMO
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Thermo Fisher Scientific Q1 2026 Earnings Call Highlights
- Revenue Growth: Thermo Fisher Scientific reported a 6% increase in Q1 2026 revenue to $11.01 billion, with adjusted EPS at $5.44, indicating strong market performance and a solid financial foundation.
- Acquisition and Investment: The company completed the acquisition of Clario, contributing $30 million in revenue and $0.01 to adjusted EPS, while repurchasing $3 billion in shares and increasing dividends by 10%, reflecting confidence in future growth.
- Outlook Upgrade: Thermo Fisher raised its full-year revenue guidance to $47.3 billion to $48.1 billion and adjusted EPS to $24.64 to $25.12, reflecting a strong start to the year and the positive impact of the Clario acquisition.
- Strategic Collaborations: The company announced strategic partnerships with NVIDIA and SHL Medical, leveraging its Ridgefield, New Jersey sterile fill-finish site to provide comprehensive solutions, further enhancing its market competitiveness and service capabilities.
See More
Thermo Fisher Scientific Stock Drops Approximately 9% Following Q1 Earnings Report
- Stock Performance: The stock of Thermo Fisher Scientific has dropped approximately 9% following the release of its Q1 results.
- Market Reaction: Investors reacted negatively to the earnings report, impacting the company's market valuation.
See More
JP Morgan Lowers Target Price for Thermo Fisher Scientific Inc. to $600 from $710
- Target Price Adjustment: JP Morgan has reduced its target price for Thermo Fisher Scientific from $710 to $600.
- Market Impact: This adjustment reflects changes in market conditions and expectations for the company's performance.
See More
US Stocks Close Lower Amid Iran Tensions and Mixed Economic Data
- Market Weakness: On Thursday, the S&P 500 index fell by 0.41%, the Dow Jones Industrial Average dropped by 0.36%, and the Nasdaq 100 declined by 0.57%, reflecting heightened investor concerns over the escalating tensions in Iran, which erased earlier gains.
- Mixed Economic Data: Weekly initial unemployment claims rose by 6,000 to 214,000, indicating a weaker labor market than the expected 210,000, while the Chicago Fed national activity index fell to -0.20, signaling a slowdown in economic growth.
- Rising Oil Prices: WTI crude oil prices surged over 3% due to tensions in the Strait of Hormuz, potentially exacerbating the global energy crisis and influencing market sentiment and inflation expectations.
- Earnings Reports Highlight: Despite the overall market weakness, 81% of S&P 500 companies reported better-than-expected earnings, with Q1 earnings projected to rise by 12% year-over-year, showcasing resilience in certain sectors, particularly chipmakers like Texas Instruments, which rose over 19%.
See More
US Stocks Slightly Up, Led by Chipmakers
- Chipmaker Rally: Texas Instruments (TXN) surged over 16% after reporting Q1 revenue of $4.83 billion, exceeding the consensus of $4.53 billion, and forecasting Q2 revenue between $5.00 billion and $5.40 billion, solidifying its leadership in the semiconductor market.
- Strong Rental Performance: United Rentals (URI) saw its stock rise over 20% after posting Q1 revenue of $3.99 billion, above the consensus of $3.88 billion, and raising its full-year revenue forecast to $16.9 billion-$17.4 billion, indicating robust market demand and growth potential.
- Software Sector Weakness: ServiceNow (NOW) dropped more than 16% after cutting its full-year gross margin forecast to 81.5%, below the consensus of 82.1%, reflecting challenges in the software industry that may impact investor confidence.
- Mixed Economic Data: Weekly initial jobless claims rose to 214,000, exceeding expectations of 210,000, indicating a weaker labor market, while the April S&P manufacturing PMI increased to 54.0, surpassing expectations of 52.5, suggesting a rebound in manufacturing activity.
See More
Market Rotation: Software to Hardware Shift
- Market Dynamics: During Thursday's livestream, Jim Cramer highlighted that the S&P 500 and Nasdaq indices experienced a rotation from software to hardware following a 17% drop in ServiceNow shares, which, despite beating earnings expectations, cited the Iran war as a drag on subscription revenue growth.
- Hardware Stock Performance: Chip designer Arm led the hardware rally with a roughly 6% increase, reaching all-time highs, and has risen over 20% since we initiated a position three days ago; Jim called it an 'incredible move' but expressed concerns about CEO Rene Haas's expanded role at SoftBank.
- Procter & Gamble Outlook: Procter & Gamble's stock rose over 1%, trading around $145, with Jim indicating he would consider buying more if it drops below $140, expressing optimism about new CEO Shailesh Jejurikar, while the Street anticipates about 1% EPS growth and slightly below 2% organic revenue growth.
- Quick Recap: In Thursday's rapid-fire segment, Jim covered stocks including American Express, IBM, Tesla, Texas Instruments, and Thermo Fisher, emphasizing his ongoing focus on these companies and reminding subscribers that they will receive trade alerts before any transactions.
See More
Thermo Fisher Scientific Q1 2026 Earnings Call Highlights
- Revenue Growth: Thermo Fisher Scientific reported a 6% increase in Q1 2026 revenue to $11.01 billion, with adjusted EPS at $5.44, indicating strong market performance and a solid financial foundation.
- Acquisition and Investment: The company completed the acquisition of Clario, contributing $30 million in revenue and $0.01 to adjusted EPS, while repurchasing $3 billion in shares and increasing dividends by 10%, reflecting confidence in future growth.
- Outlook Upgrade: Thermo Fisher raised its full-year revenue guidance to $47.3 billion to $48.1 billion and adjusted EPS to $24.64 to $25.12, reflecting a strong start to the year and the positive impact of the Clario acquisition.
- Strategic Collaborations: The company announced strategic partnerships with NVIDIA and SHL Medical, leveraging its Ridgefield, New Jersey sterile fill-finish site to provide comprehensive solutions, further enhancing its market competitiveness and service capabilities.
See More
Thermo Fisher Scientific Stock Drops Approximately 9% Following Q1 Earnings Report
- Stock Performance: The stock of Thermo Fisher Scientific has dropped approximately 9% following the release of its Q1 results.
- Market Reaction: Investors reacted negatively to the earnings report, impacting the company's market valuation.
See More
JP Morgan Lowers Target Price for Thermo Fisher Scientific Inc. to $600 from $710
- Target Price Adjustment: JP Morgan has reduced its target price for Thermo Fisher Scientific from $710 to $600.
- Market Impact: This adjustment reflects changes in market conditions and expectations for the company's performance.
See More
US Stocks Close Lower Amid Iran Tensions and Mixed Economic Data
- Market Weakness: On Thursday, the S&P 500 index fell by 0.41%, the Dow Jones Industrial Average dropped by 0.36%, and the Nasdaq 100 declined by 0.57%, reflecting heightened investor concerns over the escalating tensions in Iran, which erased earlier gains.
- Mixed Economic Data: Weekly initial unemployment claims rose by 6,000 to 214,000, indicating a weaker labor market than the expected 210,000, while the Chicago Fed national activity index fell to -0.20, signaling a slowdown in economic growth.
- Rising Oil Prices: WTI crude oil prices surged over 3% due to tensions in the Strait of Hormuz, potentially exacerbating the global energy crisis and influencing market sentiment and inflation expectations.
- Earnings Reports Highlight: Despite the overall market weakness, 81% of S&P 500 companies reported better-than-expected earnings, with Q1 earnings projected to rise by 12% year-over-year, showcasing resilience in certain sectors, particularly chipmakers like Texas Instruments, which rose over 19%.
See More
US Stocks Slightly Up, Led by Chipmakers
- Chipmaker Rally: Texas Instruments (TXN) surged over 16% after reporting Q1 revenue of $4.83 billion, exceeding the consensus of $4.53 billion, and forecasting Q2 revenue between $5.00 billion and $5.40 billion, solidifying its leadership in the semiconductor market.
- Strong Rental Performance: United Rentals (URI) saw its stock rise over 20% after posting Q1 revenue of $3.99 billion, above the consensus of $3.88 billion, and raising its full-year revenue forecast to $16.9 billion-$17.4 billion, indicating robust market demand and growth potential.
- Software Sector Weakness: ServiceNow (NOW) dropped more than 16% after cutting its full-year gross margin forecast to 81.5%, below the consensus of 82.1%, reflecting challenges in the software industry that may impact investor confidence.
- Mixed Economic Data: Weekly initial jobless claims rose to 214,000, exceeding expectations of 210,000, indicating a weaker labor market, while the April S&P manufacturing PMI increased to 54.0, surpassing expectations of 52.5, suggesting a rebound in manufacturing activity.
See More
Market Rotation: Software to Hardware Shift
- Market Dynamics: During Thursday's livestream, Jim Cramer highlighted that the S&P 500 and Nasdaq indices experienced a rotation from software to hardware following a 17% drop in ServiceNow shares, which, despite beating earnings expectations, cited the Iran war as a drag on subscription revenue growth.
- Hardware Stock Performance: Chip designer Arm led the hardware rally with a roughly 6% increase, reaching all-time highs, and has risen over 20% since we initiated a position three days ago; Jim called it an 'incredible move' but expressed concerns about CEO Rene Haas's expanded role at SoftBank.
- Procter & Gamble Outlook: Procter & Gamble's stock rose over 1%, trading around $145, with Jim indicating he would consider buying more if it drops below $140, expressing optimism about new CEO Shailesh Jejurikar, while the Street anticipates about 1% EPS growth and slightly below 2% organic revenue growth.
- Quick Recap: In Thursday's rapid-fire segment, Jim covered stocks including American Express, IBM, Tesla, Texas Instruments, and Thermo Fisher, emphasizing his ongoing focus on these companies and reminding subscribers that they will receive trade alerts before any transactions.
See More
